Medicine for reducing uric acid

A technology for lowering uric acid and drugs, which can be used in drug combinations, pharmaceutical formulations, plant raw materials, etc., and can solve problems such as lack of research on synergistic effects of tea functional components

Inactive Publication Date: 2012-10-03
CHANGSHA XUANHUANG BIO TECH
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] It can be seen that the above functional components of tea have the functions of anti-oxidation, lowering blood fat, lowering blood pressure, anticoagulation, regulating immunity, reducing uric acid, antagonizing blood vessel damage, etc., but each functional component only has its specific effect in one aspect. Biological function, the current research at home and abroad is limited to the study of the biological mechanism of a single functional component of tea, lack of research on the synergistic effect of multiple functional components ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for reducing uric acid
  • Medicine for reducing uric acid
  • Medicine for reducing uric acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Male Kunming mice were divided into control group and hyperuricemia group [intraperitoneal injection of oxonic acid potassium salt method (300mg / kg one-time intraperitoneal injection) to prepare animal model of hyperuricemia], hyperuricemia group and They were randomly divided into a model group and a uric acid-lowering drug (200mg / kg) treatment group. After one week of treatment, the rats were killed to detect the blood uric acid level. The proportions of the components of the present invention and the orthogonal test were used to determine the proportions of the components of the uric acid-lowering drug, and the results shown in Table 1 were obtained.

[0014] Table 1 shows that various components reduce blood uric acid in hyperuricemia model mice ( μmol / L):

[0015] Table 1

[0016]

[0017]

[0018] As shown in Table 1, any single component in catechin, tea pigment, tea compound polysaccharide, theanine, vitamin C, and proanthocyanidin has different degrees...

Embodiment 2

[0020] Male Kunming mice were divided into control group and hyperuricemia group [the method of intraperitoneal injection of oxonic acid potassium salt (300mg / kg one-time intraperitoneal injection) to prepare animal model of hyperuricemia], hyperuricemia group and They were randomly divided into model group, benzbromarone (20mg / kg) treatment group, allopurinol (40mg / kg) treatment group, compound uric acid-lowering drugs (catechin 30%, tea pigment 10%, tea compound polysaccharide 15%) %, theanine 5%, vitamin C 10%, proanthocyanidins 30%, 200mg / kg) treatment group, the treatment group was given benzbromarone 20mg / kg, allopurinol 40mg / kg, and uric acid-lowering drugs 200mg / kg. Stomach for 7 days, observed changes in blood uric acid, blood lipids, xanthine oxidase activity, and renal function levels of mice in each group, and the results shown in Table 2 were obtained.

[0021] Table 2 shows the comparison of concentrations of blood uric acid, cholesterol, triacylglycerol, urea ni...

Embodiment 3

[0026] Male Kunming mice were divided into control group and hyperuricemia group [the method of intraperitoneal injection of oxonic acid potassium salt (300mg / kg one-time intraperitoneal injection) to prepare animal model of hyperuricemia], hyperuricemia group and They were randomly divided into model group, benzbromarone (20mg / kg) treatment group, allopurinol (40mg / kg) treatment group, uric acid-lowering drugs (catechin 20%, tea pigment 20%, tea compound polysaccharide 10%) , theanine 20%, vitamin C 20%, proanthocyanidins 10%, 200mg / kg) treatment group, the treatment group were given 20mg / kg benzbromarone, 40mg / kg allopurinol, 200mg / kg lowering uric acid drugs After 7 days, the changes of blood uric acid, blood lipid, xanthine oxidase activity, and renal function levels of mice in each group were observed, and the results shown in Figure 3 were obtained. Table 3 Comparison of blood uric acid, cholesterol, triacylglycerol, blood urea nitrogen, creatinine, and xanthine oxidase ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicine for reducing the uric acid. The medicine comprises the following components in percent by weight: 10%-40% of catechinic acid, 10%-20% of tea pigment, 10%-20% of tea compound sugar, 5%-20% of theanine, 5%-20% of vitamin C, 10%-30% of procyanidine. The medicine provided by the invention has the advantages that the uric acid is reduced by multiple aspects of inhibiting the activity of xanthine oxidase, directly decomposing the uric acid, improving the kidney function, promoting the excretion of uric acid and protecting the blood vessels and the like, and the harm to the health of a human body is eliminated. Compared with the traditional medicine for reducing the uric acid, the medicine provided by the invention has the beneficial effects that except the function of reducing the uric acid, the effect of inhibiting the activity of the xanthine oxidase is also obviously improved, the blood fat and the kidney function are also obviously improved and no side effect is caused.

Description

technical field [0001] The invention relates to a compound medicine, in particular to a uric acid-lowering medicine. Background technique [0002] Uric acid is the final product of human purine metabolism, usually catalyzed by xanthine oxidase. Under normal circumstances, the production and excretion of uric acid in the human body maintain a dynamic balance. Excessive production or insufficient excretion of uric acid can increase blood uric acid levels. [0003] Epidemiological studies have found that with the improvement of human living standards and changes in dietary structure, the prevalence of hyperuricemia is on the rise worldwide. A large number of clinical epidemiological studies have shown that hyperuricemia is not only an independent risk factor for hypertension, cardiovascular and cerebrovascular diseases, and diabetes, but also long-term asymptomatic hyperuricemia is the main pathogenic factor of chronic kidney disease. Hyperuricemia and primary gout are signifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/82A61P19/06A61K31/198A61K31/353A61K31/375
Inventor 何小解
Owner CHANGSHA XUANHUANG BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap